Moderna Rises as Cancer-Vaccine Momentum and Pipeline Visibility Stay in Focus

Moderna, Inc. (MRNA) is up 6.9% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is continued investor enthusiasm around Moderna’s personalized cancer vaccine program after the company and its partner disclosed positive Phase 3 melanoma results in August, a result that materially changed how the market values Moderna’s oncology platform. The move also appears to be supported by fresh pipeline visibility from recent conference appearances and upcoming medical-meeting presentations, which keep attention on potential regulatory and commercial follow-through.

Details:

Moderna and its partner said their Phase 3 INTerpath-001 study met key endpoints in resected stage IIB-IV melanoma, showing improvements in recurrence-free survival and distant metastasis-free survival versus KEYTRUDA alone.

The company said the data would be presented at a major international medical meeting and shared with regulators, giving investors a clearer path toward future filings.

Recent company event listings and conference appearances have kept the oncology story active, including discussion of pipeline progress and the broader mRNA platform beyond COVID.

Moderna also has updated 2026-2027 COVID vaccine products in the market, which adds another near-term commercial support point even if today’s gain looks primarily oncology-driven.

Sources:

Moderna, FDA, MarketScreener

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MRNA Insider Trading Activity

$MRNA insiders have traded $MRNA stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.

Here’s a breakdown of recent trading of $MRNA stock by insiders over the last 6 months:

STEPHANE BANCEL (Chief Executive Officer) has made 0 purchases and 4 sales selling 499,246 shares for an estimated $28,715,011.
STEPHEN HOGE (President) has made 0 purchases and 5 sales selling 240,583 shares for an estimated $20,618,266.
JAMES M MOCK (Chief Financial Officer) has made 0 purchases and 2 sales selling 34,836 shares for an estimated $4,685,093.
SHANNON THYME KLINGER (Chief Legal Officer) has made 0 purchases and 2 sales selling 6,942 shares for an estimated $659,316.
NOUBAR AFEYAN sold 9,263 shares for an estimated $433,878
ABBAS HUSSAIN sold 5,682 shares for an estimated $264,951

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$MRNA Hedge Fund Activity

We have seen 381 institutional investors add shares of $MRNA stock to their portfolio, and 398 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC added 6,187,867 shares (+13.5%) to their portfolio in Q2 2026, for an estimated $433,336,326
D. E. SHAW & CO., INC. removed 5,157,808 shares (-99.5%) from their portfolio in Q2 2026, for an estimated $361,201,294
PRICE T ROWE ASSOCIATES INC /MD/ added 4,850,982 shares (+656.8%) to their portfolio in Q2 2026, for an estimated $339,714,269
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 4,838,884 shares (+inf%) to their portfolio in Q2 2026, for an estimated $338,867,046
CAPITAL WORLD INVESTORS added 3,579,302 shares (+19.1%) to their portfolio in Q2 2026, for an estimated $250,658,519
ALYESKA INVESTMENT GROUP, L.P. removed 3,490,366 shares (-86.2%) from their portfolio in Q2 2026, for an estimated $244,430,330
BAILLIE GIFFORD & CO removed 2,373,736 shares (-11.5%) from their portfolio in Q2 2026, for an estimated $166,232,732

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$MRNA Congressional Stock Trading

Members of Congress have traded $MRNA stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $MRNA stock by members of Congress over the last 6 months:

REPRESENTATIVE MARIA ELVIRA SALAZAR has traded it 2 times. They made 1 purchase worth up to $15,000 on 08/19 and 1 sale worth up to $15,000 on 08/19.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$MRNA Price Targets

Multiple analysts have issued price targets for $MRNA recently. We have seen 8 analysts offer price targets for $MRNA in the last 6 months, with a median target of $46.5.

Here are some recent targets:

Matthew Harrison from Morgan Stanley set a target price of $39.0 on 07/08/2026
Luca Issi from RBC Capital set a target price of $45.0 on 07/07/2026
Dimple Gosai from B of A Securities set a target price of $38.0 on 07/07/2026
Edward Tenthoff from Piper Sandler set a target price of $77.0 on 06/26/2026
Salveen Richter from Goldman Sachs set a target price of $49.0 on 05/04/2026
Cory Kasimov from Evercore ISI Group set a target price of $50.0 on 05/04/2026
Eliana Merle from UBS set a target price of $45.0 on 05/04/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.